Acetaminophen is a suitable treatment for moderate osteoarthritis pain of the knee .
A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis
Osteoarthritis Cartilage. 2009 Jan;17(1):1-7. Epub 2008 Jul 21403 patients suffering from moderate pain associated with osteoarthritis (OA) of the knee were randomized into three groups. The groups consisted of an acetaminophen extended-release (APAP ER) group, a 12.5 mg rofecoxib group, and a 25 mg rofecoxib group. Following four weeks of treatment each group produced a significant reduction in WOMAC pain scores from baseline measures. APAP ER was found to be non-inferior, in terms of reduction in pain scores, when compared to the 12.5mg dose of rofecoxib. However, this non-inferiority was not established in comparison to the larger rofecoxib dose.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
